vs
Side-by-side financial comparison of Cardiff Oncology, Inc. (CRDF) and DYADIC INTERNATIONAL INC (DYAI). Click either name above to swap in a different company.
DYADIC INTERNATIONAL INC is the larger business by last-quarter revenue ($565.5K vs $243.0K, roughly 2.3× Cardiff Oncology, Inc.). DYADIC INTERNATIONAL INC runs the higher net margin — -277.1% vs -2969.5%, a 2692.4% gap on every dollar of revenue. On growth, Cardiff Oncology, Inc. posted the faster year-over-year revenue change (62.0% vs -30.8%). Over the past eight quarters, DYADIC INTERNATIONAL INC's revenue compounded faster (30.0% CAGR vs 8.9%).
Dyadic International Inc is a global biotechnology firm that develops and manufactures proprietary high-performance enzymes, biologic therapies and sustainable bioproducts. It serves pharma, industrial biotech, agricultural and environmental sectors across North America, Europe and Asia Pacific, using its patented C1 gene expression platform to drive cost-effective scalable biomanufacturing.
CRDF vs DYAI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $243.0K | $565.5K |
| Net Profit | $-7.2M | $-1.6M |
| Gross Margin | — | — |
| Operating Margin | -3221.0% | -271.6% |
| Net Margin | -2969.5% | -277.1% |
| Revenue YoY | 62.0% | -30.8% |
| Net Profit YoY | 38.8% | -1.1% |
| EPS (diluted) | $-0.11 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $243.0K | $565.5K | ||
| Q3 25 | $120.0K | $1.2M | ||
| Q2 25 | $121.0K | $966.6K | ||
| Q1 25 | $109.0K | $393.6K | ||
| Q4 24 | $150.0K | $817.4K | ||
| Q3 24 | $165.0K | $2.0M | ||
| Q2 24 | $163.0K | $385.9K | ||
| Q1 24 | $205.0K | $334.6K |
| Q4 25 | $-7.2M | $-1.6M | ||
| Q3 25 | $-11.3M | $-2.0M | ||
| Q2 25 | $-13.9M | $-1.8M | ||
| Q1 25 | $-13.4M | $-2.0M | ||
| Q4 24 | $-11.8M | $-1.6M | ||
| Q3 24 | $-11.9M | $-203.5K | ||
| Q2 24 | $-11.8M | $-2.0M | ||
| Q1 24 | $-10.0M | $-2.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | 12.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 56.8% | ||
| Q3 24 | — | 79.8% | ||
| Q2 24 | — | 21.8% | ||
| Q1 24 | — | 57.0% |
| Q4 25 | -3221.0% | -271.6% | ||
| Q3 25 | -9978.3% | -165.3% | ||
| Q2 25 | -12212.4% | -178.9% | ||
| Q1 25 | -13194.5% | -508.8% | ||
| Q4 24 | -8381.3% | -187.2% | ||
| Q3 24 | -7637.0% | -10.4% | ||
| Q2 24 | -7696.3% | -529.3% | ||
| Q1 24 | -5333.2% | -635.2% |
| Q4 25 | -2969.5% | -277.1% | ||
| Q3 25 | -9381.7% | -169.7% | ||
| Q2 25 | -11523.1% | -185.6% | ||
| Q1 25 | -12324.8% | -515.2% | ||
| Q4 24 | -7858.0% | -189.7% | ||
| Q3 24 | -7184.8% | -10.4% | ||
| Q2 24 | -7225.8% | -530.0% | ||
| Q1 24 | -4883.4% | -600.6% |
| Q4 25 | $-0.11 | — | ||
| Q3 25 | $-0.17 | $-0.06 | ||
| Q2 25 | $-0.21 | $-0.06 | ||
| Q1 25 | $-0.20 | — | ||
| Q4 24 | $-0.22 | — | ||
| Q3 24 | $-0.25 | $-0.01 | ||
| Q2 24 | $-0.26 | $-0.07 | ||
| Q1 24 | $-0.22 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $58.3M | $7.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $45.4M | $1.2M |
| Total Assets | $61.9M | $9.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $58.3M | $7.3M | ||
| Q3 25 | $60.6M | $8.9M | ||
| Q2 25 | $71.0M | $5.0M | ||
| Q1 25 | $79.9M | $7.4M | ||
| Q4 24 | $91.7M | $9.3M | ||
| Q3 24 | $57.7M | $5.9M | ||
| Q2 24 | $60.3M | $6.1M | ||
| Q1 24 | $67.2M | $10.6M |
| Q4 25 | $45.4M | $1.2M | ||
| Q3 25 | $48.8M | $2.6M | ||
| Q2 25 | $58.6M | $-529.7K | ||
| Q1 25 | $70.9M | $923.6K | ||
| Q4 24 | $82.9M | $2.5M | ||
| Q3 24 | $49.4M | $3.4M | ||
| Q2 24 | $52.4M | $3.2M | ||
| Q1 24 | $60.9M | $4.5M |
| Q4 25 | $61.9M | $9.9M | ||
| Q3 25 | $63.8M | $11.7M | ||
| Q2 25 | $75.7M | $8.1M | ||
| Q1 25 | $84.8M | $7.9M | ||
| Q4 24 | $97.2M | $9.9M | ||
| Q3 24 | $62.9M | $10.8M | ||
| Q2 24 | $66.1M | $10.6M | ||
| Q1 24 | $74.0M | $12.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.0M | $-1.8M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.0M | $-1.8M | ||
| Q3 25 | $-10.8M | $-1.9M | ||
| Q2 25 | $-8.3M | $-130.0K | ||
| Q1 25 | $-12.8M | $-1.9M | ||
| Q4 24 | $-10.3M | $-696.4K | ||
| Q3 24 | $-10.5M | $-201.1K | ||
| Q2 24 | $-9.2M | $-2.0M | ||
| Q1 24 | $-7.7M | $-1.1M |
| Q4 25 | — | — | ||
| Q3 25 | $-10.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $-7.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | -9043.3% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -3814.6% | — |
| Q4 25 | — | — | ||
| Q3 25 | 15.0% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 39.0% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
